BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19432895)

  • 21. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
    Warmuth M; Danhauser-Riedl S; Hallek M
    Ann Hematol; 1999 Feb; 78(2):49-64. PubMed ID: 10089019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
    Nakahara F; Sakata-Yanagimoto M; Komeno Y; Kato N; Uchida T; Haraguchi K; Kumano K; Harada Y; Harada H; Kitaura J; Ogawa S; Kurokawa M; Kitamura T; Chiba S
    Blood; 2010 Apr; 115(14):2872-81. PubMed ID: 19861684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment, characterization, and chromosomal analysis of new leukemic cell lines derived from MT/p210bcr/abl transgenic mice.
    Honda H; Ohno S; Takahashi T; Takatoku M; Yazaki Y; Hirai H
    Exp Hematol; 1998 Mar; 26(3):188-97. PubMed ID: 9502614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases.
    Grossmann V; Kohlmann A; Zenger M; Schindela S; Eder C; Weissmann S; Schnittger S; Kern W; Müller MC; Hochhaus A; Haferlach T; Haferlach C
    Leukemia; 2011 Mar; 25(3):557-60. PubMed ID: 21274004
    [No Abstract]   [Full Text] [Related]  

  • 27. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
    Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU
    Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice.
    Honda H; Fujii T; Takatoku M; Mano H; Witte ON; Yazaki Y; Hirai H
    Blood; 1995 May; 85(10):2853-61. PubMed ID: 7537982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
    Dhingra K; Talpaz M; Kantarjian H; Ku S; Rothberg J; Gutterman JU; Kurzrock R
    Leukemia; 1991 Mar; 5(3):191-5. PubMed ID: 2013978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coexistence of inversion 16 and the Philadelphia chromosome comprising P190 BCR/ABL in chronic myeloid leukemia blast crisis.
    Ninomiya S; Kanemura N; Tsurumi H; Kasahara S; Hara T; Yamada T; Moriwaki H
    Int J Hematol; 2011 Jun; 93(6):806-810. PubMed ID: 21523337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Animal models of BCR/ABL-induced leukemias.
    Daley GQ
    Leuk Lymphoma; 1993; 11 Suppl 1():57-60. PubMed ID: 8251918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl.
    Seo S; Nakamoto T; Takeshita M; Lu J; Sato T; Suzuki T; Kamikubo Y; Ichikawa M; Noda M; Ogawa S; Honda H; Oda H; Kurokawa M
    Cancer Sci; 2011 Dec; 102(12):2109-17. PubMed ID: 21848808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
    Okabe M
    Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cadherin-13 in primary and blast crisis chronic myeloid leukaemia: declining expression and negative correlation with the BCR/ABL fusion gene.
    Mu HJ; Xie R; Shen YF; Jiang YQ; Zeng YJ
    Br J Biomed Sci; 2009; 66(1):20-4. PubMed ID: 19348122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
    Gaiger A; Henn T; Hörth E; Geissler K; Mitterbauer G; Maier-Dobersberger T; Greinix H; Mannhalter C; Haas OA; Lechner K; Lion T
    Blood; 1995 Sep; 86(6):2371-8. PubMed ID: 7662984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The molecular pathology of chronic myelogenous leukaemia.
    Kurzrock R; Talpaz M
    Br J Haematol; 1991 Oct; 79 Suppl 1():34-7. PubMed ID: 1931706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
    Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
    Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.